GRI Bio (GRI) said Monday it has received a "decision to grant" notice from Japan's Patent Office for a patent application covering the use of natural killer T cell modulators to prevent and treat inflammatory diseases.
The patent covers claims, which include compositions and methods, for modulating type 2 and/or type 1 invariant natural killer T cells to prevent and treat the conditions, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments